| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8338485 | ALLERGAN | Compositions for the treatment of CNS-related conditions |
Nov, 2025
(2 years from now) | |
| US8173708 | ALLERGAN | Method and composition for administering an NMDA receptor antagonist to a subject |
Nov, 2025
(2 years from now) | |
| US8362085 | ALLERGAN | Method for administering an NMDA receptor antagonist to a subject |
Nov, 2025
(2 years from now) | |
| US8338486 | ALLERGAN | Methods for the treatment of CNS-related conditions |
Nov, 2025
(2 years from now) | |
| US8283379 | ALLERGAN | Methods and compositions for the treatment of CNS-related conditions |
Nov, 2025
(2 years from now) | |
| US8580858 | ALLERGAN | Compositions for the treatment of CNS-related conditions |
Nov, 2025
(2 years from now) | |
| US8329752 | ALLERGAN | Composition for administering an NMDA receptor antagonist to a subject |
Nov, 2025
(2 years from now) | |
| US8598233 | ALLERGAN | Method for administering an NMDA receptor antagonist to a subject |
Nov, 2025
(2 years from now) | |
| US8168209 | ALLERGAN | Method and composition for administering an NMDA receptor antagonist to a subject |
Nov, 2025
(2 years from now) | |
| US8293794 | ALLERGAN | Methods and compositions for the treatment of CNS-related conditions |
Nov, 2025
(2 years from now) | |
|
US8329752 (Pediatric) | ALLERGAN | Composition for administering an NMDA receptor antagonist to a subject |
May, 2026
(2 years from now) | |
|
US8283379 (Pediatric) | ALLERGAN | Methods and compositions for the treatment of CNS-related conditions |
May, 2026
(2 years from now) | |
|
US8173708 (Pediatric) | ALLERGAN | Method and composition for administering an NMDA receptor antagonist to a subject |
May, 2026
(2 years from now) | |
|
US8362085 (Pediatric) | ALLERGAN | Method for administering an NMDA receptor antagonist to a subject |
May, 2026
(2 years from now) | |
|
US8598233 (Pediatric) | ALLERGAN | Method for administering an NMDA receptor antagonist to a subject |
May, 2026
(2 years from now) | |
|
US8168209 (Pediatric) | ALLERGAN | Method and composition for administering an NMDA receptor antagonist to a subject |
May, 2026
(2 years from now) | |
| US8039009 | ALLERGAN | Modified release formulations of memantine oral dosage forms |
Mar, 2029
(5 years from now) | |
|
US8039009 (Pediatric) | ALLERGAN | Modified release formulations of memantine oral dosage forms |
Sep, 2029
(5 years from now) | |
| US8058291 | ALLERGAN | Methods and compositions for the treatment of CNS-related conditions |
Dec, 2029
(6 years from now) | |
Namzaric is owned by Allergan.
Namzaric contains Donepezil Hydrochloride; Memantine Hydrochloride.
Namzaric has a total of 19 drug patents out of which 0 drug patents have expired.
Namzaric was authorised for market use on 23 December, 2014.
Namzaric is available in capsule, extended release;oral dosage forms.
Namzaric can be used as memantine hcl/donepezil hcl combination for the treatment of moderate to severe dementia of the alzheimer's type.
The generics of Namzaric are possible to be released after 05 December, 2029.
Drugs and Companies using DONEPEZIL HYDROCHLORIDE; MEMANTINE HYDROCHLORIDE ingredient
Market Authorisation Date: 23 December, 2014
Treatment: Memantine hcl/donepezil hcl combination for the treatment of moderate to severe dementia of the alzheimer's type
Dosage: CAPSULE, EXTENDED RELEASE;ORAL
NAMZARIC family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic